Sanofi and Cheplapharm have announced plans to establish a new strategic partnership focused on the management of mature medicines. Under the proposed agreement, Cheplapharm will take over 20 mature medicines and three Sanofi manufacturing sites worldwide, while Sanofi will receive a 26.4% equity stake in Cheplapharm.
The partnership builds on a collaboration between the two companies that began in 2014. Sanofi said the arrangement is intended to allow mature and innovative medicines to benefit from operating models tailored to their different manufacturing, regulatory and commercial requirements.
Three Sanofi Manufacturing Sites to Transfer
The proposed transaction includes the transfer of three manufacturing facilities:
Csanyikvölgy, Hungary – approximately 400 employees
Jurong, Singapore – approximately 100 employees
Ploërmel, France – approximately 65 employees
According to Sanofi, employees at these facilities would continue their activities under existing employment arrangements and collective agreements. The companies also plan to work together to maintain manufacturing quality and continuity of supply during the transition.
The medicines being transferred include Lovenox/Clexane (enoxaparin), an established anticoagulant medicine. Sanofi noted that the transaction excludes the U.S. rights for the product.
Cheplapharm said the transaction will add products to its established-medicines portfolio while also bringing manufacturing capabilities and expertise associated with Lovenox/Clexane.
The commercial transfer of the medicine portfolio is expected to begin in Q1 2027, followed by the transfer of the manufacturing sites. Completion is expected by Q3 2027, subject to employee consultation procedures, regulatory approvals and other customary closing conditions. Sanofi stated that the proposed transaction is not expected to affect its 2026 financial guidance. Additional financial details are expected to be provided at a later stage.
The company said the partnership will enable Sanofi to continue concentrating its efforts on innovative medicines, while Cheplapharm will focus on supporting the transferred established medicines through the next stage of their lifecycle.
